VOLUME - 15, ISSUE - 08, AUGUST - 2026 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

General Medicine

ANTIBIOTIC-DRIVEN GUT MICROBIOME DYSBIOSIS: RESISTOME DYNAMICS, METABOLIC DISRUPTION, AND PATHS TO RESTORATION

Dr. Vivek Singla	Junior Resident, Department of General Medicine, G S Medical College and Hospital, Pilkhuwa, Hapur, Uttar Pradesh, India - 245304
Dr. Gaurav Sharma	Associate Professor, Department of General Medicine, G S Medical College and Hospital, Pilkhuwa, Hapur, Uttar Pradesh, India - 245304
Dr. Shagun Pundir	Assistant Professor, Department of General Medicine, G S Medical College and Hospital, Pilkhuwa, Hapur, Uttar Pradesh, India - 245304
Dr. Sunil Kumar Gupta	Professor, Department of General Medicine, G S Medical College and Hospital, Pilkhuwa, Hapur, Uttar Pradesh, India - 245304
Dr. Shikha Srivastava*	Junior Resident, Department of General Medicine, G S Medical College and Hospital, Pilkhuwa, Hapur, Uttar Pradesh, India – 245304*Corresponding Author

ABSTRACT

Background: The human gut microbiome is a complex ecosystem essential for host health. Antibiotic exposure disrupts this ecosystem, leading to dysbiosis with far-reaching consequences including antimicrobial resistance (AMR) gene proliferation and metabolic dysfunction. This review examines the mechanisms of antibiotic-driven gut microbiome dysbiosis, resistome dynamics, metabolic consequences, and evidence-based strategies for restoration. **Methods:** A comprehensive narrative review was conducted synthesizing evidence from preclinical studies, clinical trials, and meta-analyses on antibiotic-induced microbiome alterations, resistome expansion, metabolic disruptions, and restoration strategies. **Results:** Antibiotics reduce gut microbial diversity, deplete beneficial taxa (Bifidobacteria, Lactobacilli), and enrich opportunistic pathogens. The gut resistome expands through horizontal gene transfer, with AMR genes persisting for months to years post-treatment. Metabolic disruption includes reduced short-chain fatty acid production, altered bile acid metabolism, and immune dysregulation. Restoration strategies show variable efficacy: probiotics achieve 40-60% diversity recovery, FMT demonstrates 80-90% efficacy for recurrent C. difficile infection, and dietary interventions support gradual restoration. **Conclusion:** Antibiotic-induced gut dysbiosis is characterized by reduced diversity, resistome expansion, and significant metabolic disruption. While restoration is achievable through targeted interventions, prevention through antibiotic stewardship remains paramount.

KEYWORDS : Gut Microbiome, Dysbiosis, Antimicrobial Resistance, Resistome, Probiotics, Faecal Microbiota Transplantation

INTRODUCTION

The human gut harbours trillions of microorganisms—collectively termed the gut microbiome—that play indispensable roles in nutrient metabolism, immune system development, pathogen protection, and maintenance of intestinal barrier integrity [1]. The gut microbiome comprises approximately 500-1000 bacterial species, with Firmicutes and Bacteroidetes dominating, and exhibits remarkable interindividual diversity shaped by diet, genetics, environment, and medication use [2].

Antibiotics are among the most widely prescribed medications globally, with an estimated 30-50% of prescriptions considered unnecessary or inappropriate [3]. While antibiotics are life-saving in treating bacterial infections, their collateral damage to the gut microbiome is profound. Antibiotic exposure disrupts the delicate ecological balance, leading to dysbiosis—characterised by reduced diversity, depletion of beneficial taxa, and expansion of opportunistic pathogens [4].

Beyond immediate effects, antibiotic-driven dysbiosis facilitates the proliferation and dissemination of antimicrobial resistance genes (the "resistome") through horizontal gene transfer, posing a global threat [5]. Furthermore, microbial depletion impairs critical metabolic functions including short-chain fatty acid (SCFA) production, bile acid metabolism, and vitamin synthesis [6]. This review synthesises current understanding of antibiotic-driven gut microbiome dysbiosis, exploring resistome dynamics, metabolic consequences, and evidence-based restoration strategies.

Mechanisms Of Antibiotic-induced Dysbiosis

Direct Antimicrobial Effects

Antibiotics exert direct bactericidal or bacteriostatic effects on gut commensals, with the magnitude of disruption depending on drug spectrum, dose, and duration. Broad-spectrum antibiotics (fluoroquinolones, third-generation cephalosporins, carbapenems) cause the most extensive disruption, reducing bacterial diversity by 25-30% and altering community structure for weeks to months [7].

Depletion of Beneficial Taxa and Expansion of Pathogens

Antibiotic exposure consistently depletes beneficial taxa including Bifidobacterium, Lactobacillus, and Faecalibacterium prausnitzii, with recovery often incomplete even after six months [8]. Concurrently, opportunistic pathogens including Clostridioides difficile, Enterobacteriaceae, and vancomycin-resistant enterococci (VRE) proliferate, increasing infection risk [9]. C. difficile infection (CDI) is the most clinically significant consequence, with incidence rising 2-3 fold following antibiotic courses.

Table 1. Temporal Changes in Gut Microbiome Following

Time Point	Microbial Changes
During antibiotics (Day 1-7)	25-30% reduction in diversity; 10 - 100 fold increase in Proteobacteria
Early recovery (Week 1-4)	Partial diversity recovery; persistent depletion of beneficial taxa; resistome expansion
Mid recovery (Month 1-6)	Gradual diversity return; AMR genes persist; metabolic function impaired
Long-term (Month 6+)	Diversity may not fully recover; ARGs can persist >12 months

Antibiotic Exposure

RESISTOME DYNAMICS

The Gut Resistome and Horizontal Gene Transfer

The gut resistome encompasses all antimicrobial resistance genes (ARGs) within the gut microbial community. Even without antibiotic exposure, the gut harbours diverse ARGs as part of the "intrinsic resistome" [10]. Antibiotic treatment amplifies this reservoir by selecting for resistant organisms and promoting horizontal gene transfer (HGT) through conjugation, transformation, and transduction [11].

Persistence and Clinical Implications

ARGs can persist in the gut microbiome for months to years following antibiotic cessation. Studies demonstrate that resistance genes remain detectable 6-12 months post-treatment, with significant clinical implications: increased risk of treatment failure, reservoir for healthcare-associated infections, and contribution to community AMR burden [12].

Table 2. Resistome Changes Following Antibiotic Exposure

Parameter	Baseline (Pre-antibiotic)	Post-antibiotic (Day 7)	Post-antibiotic (Month 3)
ARG diversity	Moderate	High (2-3x increase)	Elevated (1.5-2x)
Mobile genetic elements	Low	High	Moderate
Horizontal gene transfer	Baseline	Increased (5-10x)	Elevated (2-3x)

Metabolic Disruption

Short-Chain Fatty Acid (SCFA) Depletion

SCFAs—acetate, propionate, and butyrate—are essential for colonic health, immune regulation, and energy metabolism. Butyrate serves as the primary energy source for colonocytes and maintains intestinal barrier integrity [13]. Antibiotic-induced depletion of butyrate-producing bacteria reduces SCFA production by 30-50%, impairing gut barrier function and increasing systemic inflammation.

Bile Acid Metabolism and Vitamin Synthesis

Gut microbes metabolise primary bile acids into secondary bile acids, regulating lipid metabolism and glucose homeostasis. Antibiotic disruption alters this process, contributing to metabolic dysregulation [14]. Additionally, gut microbes synthesize essential vitamins including vitamin K, B12, folate, and biotin; depletion of vitamin-producing taxa can lead to subclinical deficiencies [15].

Immune Dysregulation

The gut microbiome is critical for immune function. Antibiotic-induced dysbiosis disrupts Toll-like receptor signalling, regulatory T cell differentiation, immunoglobulin A production, and cytokine balance, contributing to increased susceptibility to infections and autoimmune conditions [16].

Table 3. Key Metabolic Consequences of Antibiotic-Induced Dysbiosis

Metabolic Parameter	Effect	Clinical Significance
Short-chain fatty acids (SCFA)	Reduced production (30-50%)	Impaired gut barrier; increased inflammation
Bile acid metabolism	Altered; reduced secondary bile acids	Metabolic dysregulation
Vitamin synthesis (K, B12, folate)	Reduced	Subclinical deficiencies
Gut barrier integrity	Impaired	Increased permeability; endotoxemia

PATHS TO RESTORATION

Probiotics and Synbiotics

Probiotics reduce antibiotic-associated diarrhoea (AAD) risk by 40-60% and promote microbial diversity recovery [17]. Effective strains include Lactobacillus rhamnosus GG (AAD prevention), Saccharomyces boulardii (C. difficile prevention), and Bifidobacterium animalis (diversity recovery). Synbiotics (probiotics + prebiotics) may offer enhanced efficacy.

Dietary Interventions and FMT

Prebiotics and high-fibre diets stimulate beneficial bacteria and support endogenous recovery. Faecal microbiota transplantation (FMT) demonstrates 80-90% efficacy for recurrent C. difficile infection and is increasingly studied for other conditions [18].

Antibiotic Stewardship

Prevention remains paramount. Antibiotic stewardship programs reduce unnecessary antibiotic use by 20-30%. Key principles include appropriate antibiotic selection (narrowest spectrum effective), shortest effective duration, and avoidance of empirical broad-spectrum use.

Table 4. Restoration Strategies: Efficacy and Evidence

Strategy	Mechanism	Efficacy	Evidence Level
Probiotics	Introduce beneficial microbes	40-60% AAD reduction	Strong (meta-analyses)
Prebiotics	Stimulate endogenous microbes	20-30% diversity improvement	Moderate
FMT	Full microbial restoration	80-90% for C. difficile	Strong
Dietary modification	Support microbial growth	30-50% diversity recovery	Moderate
Antibiotic stewardship	Prevent dysbiosis	20-30% reduction	Strong

DISCUSSION

Summary and Clinical Significance

This review demonstrates that antibiotic-driven gut microbiome dysbiosis is characterised by reduced microbial diversity, depletion of beneficial taxa, and expansion of opportunistic pathogens. The gut resistome amplifies through HGT, with ARGs persisting for months to years. Metabolic disruption includes 30-50% reduction in SCFA production, altered bile acid metabolism, and immune dysregulation [6,13].

The clinical implications extend beyond gastrointestinal symptoms. Emerging evidence links antibiotic exposure to increased risk of obesity, type 2 diabetes, inflammatory bowel disease, and allergic diseases [19]. The disrupted gut-brain axis contributes to mood disorders and cognitive impairment. Clinicians must consider these long-term consequences when prescribing antibiotics.

Recommendations and Future Directions

Based on current evidence, we recommend: prioritising antibiotic stewardship (narrow-spectrum agents, shortest duration); implementing probiotics (L. rhamnosus GG, S. boulardii) in at-risk patients; promoting dietary support (high-fibre diet, fermented foods); considering FMT for recurrent C. difficile; and monitoring for metabolic consequences.

Emerging therapies include phage therapy (targeted pathogen elimination), microbiome-based biomarkers, engineered probiotics, and AI-guided personalisation.

LIMITATIONS

This narrative review synthesises evidence from diverse sources, providing a comprehensive overview. Limitations

include heterogeneity of study methodologies, variable outcome measures, and limited long-term data on restoration strategies.

CONCLUSION

Antibiotic-driven gut microbiome dysbiosis is a clinically significant phenomenon characterised by reduced microbial diversity, resistome expansion, and profound metabolic disruption. The gut resistome amplifies through horizontal gene transfer, with antimicrobial resistance genes persisting for months to years post-treatment. Short-chain fatty acid production decreases substantially, bile acid metabolism is altered, and essential vitamin synthesis is impaired, contributing to immune dysregulation and increased risk of chronic diseases. Restoration strategies include probiotics (40-60% efficacy for antibiotic-associated diarrhoea), faecal microbiota transplantation (80-90% efficacy for recurrent C. difficile infection), and dietary interventions. However, prevention through antibiotic stewardship—using narrow-spectrum agents for the shortest effective duration—remains the most effective approach. Clinicians must recognise the collateral damage of antibiotics and implement evidence-based restoration strategies. As our understanding of the gut microbiome advances, personalised restoration strategies will become increasingly achievable, optimising patient outcomes and preserving the vital ecosystem on which human health depends.

Authors Contribution Statement

Author	Contribution
Dr. Vivek Singla	Study conception, literature search, manuscript drafting
Dr. Gaurav Sharma	Study design, clinical supervision, manuscript review
Dr. Shagun Pundir	Literature analysis, clinical content, manuscript review
Dr. Sunil Kumar Gupta	Study supervision, final review, content validation
Dr. Shikha Srivastava (Corresponding author)	Project coordination, manuscript integration, final approval

REFERENCES

1. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369-2379.
2. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220-230.
3. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits. JAMA. 2016;315(17):1864-1873.
4. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39.
5. Sommer MOA, Dantas G. Antibiotics and the resistant microbiome. Curr Opin Microbiol. 2011;14(5):556-563.
6. Blaser MJ. The microbiome revolution. J Clin Invest. 2014;124(10):4162-4165.
7. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4554-4561.
8. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology. 2010;156(11):3216-3223.
9. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13(11):790-801.
10. Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF. The human microbiome as a reservoir of antimicrobial resistance. Front Microbiol. 2013;4:87.
11. von Wintersdorff CJH, Penders J, van Niekerk JM, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front Microbiol. 2016;7:173.
12. Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836.
13. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011;13(5):517-526.
14. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41-50.
15. LeBlanc JG, Milani C, de Giori GS, et al. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr Opin Biotechnol. 2013;24(2):160-168.
16. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141.
17. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
18. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
19. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17(5):553-564.